Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Einar O. Vik Mo"'
Autor:
Lidia Luque, Karoline Skogen, Bradley J. MacIntosh, Kyrre E. Emblem, Christopher Larsson, David Bouget, Ragnhild Holden Helland, Ingerid Reinertsen, Ole Solheim, Till Schellhorn, Jonas Vardal, Eduardo E. M. Mireles, Einar O. Vik-Mo, Atle Bjørnerud
Publikováno v:
Frontiers in Radiology, Vol 4 (2024)
Standard treatment of patients with glioblastoma includes surgical resection of the tumor. The extent of resection (EOR) achieved during surgery significantly impacts prognosis and is used to stratify patients in clinical trials. In this study, we de
Externí odkaz:
https://doaj.org/article/8ad9fb81987e47c2a9570e9d61f42457
Autor:
Erlend Skaga, Cassia B. Trewin-Nybråten, Pitt Niehusmann, Tom Børge Johannesen, Kirsten Marienhagen, Leif Oltedal, Stephanie Schipman, Anne Jarstein Skjulsvik, Ole Solheim, Tora Skeidsvoll Solheim, Terje Sundstrøm, Einar O. Vik-Mo, Petter Brandal, Tor Ingebrigtsen
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background: Surveillance of incidence and survival of central nervous system tumors is essential to monitor disease burden and epidemiological changes, and to allocate health care resources. Here, we describe glioma incidence and survival trends by h
Externí odkaz:
https://doaj.org/article/2fa8de0ecb25480b99d6d0eb23fd7472
Autor:
Inge C Olsen, Thomas Henry, Corina Silvia Rueegg, Asgeir S Jakola, Hanne Blakstad, Petter Brandal, Liv Cathrine Heggebø, Ida Maria Henriksen Borgen, Hillevi Rylander, Cecilie Kiserud, Tonje Haug Nordenmark, Taran Paulsen Hellebust, Morten Egeberg Evensen, Magnus Gustavsson, Christina Ramberg, Mette Sprauten, Henriette Magelssen, Janani Moorthy, Karin Andersson, Ingela Raunert, Cecilie Moe, Carin Granlund, Dorota Goplen, Jorunn Brekke, Tor-Christian Aase Johannessen, Tora Skeidsvoll Solheim, Kirsten Marienhagen, Øyvind Humberset, Per Bergström, Måns Agrup, Ludvig Dahl, Michael Gubanski, Helene Gojon, Carl-Johan Brahme, Isabelle Rydén, Einar O Vik-Mo, Hanne C. Lie, Lars Asphaug, Maziar Hervani, Ingrid Kristensen, Rolf J Ledal, Eskil Degsell, Katja Werlenius, Malin Blomstrand
Publikováno v:
BMJ Open, Vol 13, Iss 3 (2023)
Introduction The use of proton therapy increases globally despite a lack of randomised controlled trials demonstrating its efficacy and safety. Proton therapy enables sparing of non-neoplastic tissue from radiation. This is principally beneficial and
Externí odkaz:
https://doaj.org/article/a71f1463c05244a9a4ac7eb02407367a
Autor:
Erlend Skaga, Evgeny Kulesskiy, Swapnil Potdar, Ioannis Panagopoulos, Francesca Micci, Iver A. Langmoen, Cecilie J. Sandberg, Einar O. Vik-Mo
Publikováno v:
Translational Oncology, Vol 26, Iss , Pp 101535- (2022)
Serum-free culturing of patient-derived glioblastoma biopsies enrich for glioblastoma stem cells (GSCs) and is recognized as a disease-relevant model system in glioblastoma (GBM). We hypothesized that the temozolomide (TMZ) drug sensitivity of patien
Externí odkaz:
https://doaj.org/article/776418a59d1d4543800713de62d7258d
Autor:
Erlend Skaga, Evgeny Kulesskiy, Marit Brynjulvsen, Cecilie J. Sandberg, Swapnil Potdar, Iver A. Langmoen, Aki Laakso, Emília Gaál-Paavola, Markus Perola, Krister Wennerberg, Einar O. Vik-Mo
Publikováno v:
Clinical and Translational Medicine, Vol 8, Iss 1, Pp 1-15 (2019)
Abstract Background Despite the well described heterogeneity in glioblastoma (GBM), treatment is standardized, and clinical trials investigate treatment effects at population level. Genomics-driven oncology for stratified treatments allow clinical de
Externí odkaz:
https://doaj.org/article/7b15d08a0e9049fdb540df8c7164a846
Autor:
Erlend Skaga, Evgeny Kulesskiy, Artem Fayzullin, Cecilie J. Sandberg, Swapnil Potdar, Aija Kyttälä, Iver A. Langmoen, Aki Laakso, Emília Gaál-Paavola, Markus Perola, Krister Wennerberg, Einar O. Vik-Mo
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-14 (2019)
Abstract Background A major barrier to effective treatment of glioblastoma (GBM) is the large intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials, patient heterogeneity in response to therapy is commonly obser
Externí odkaz:
https://doaj.org/article/6a612a3ed65f443b9caf0b9d6bf29bd2
Autor:
Artem Fayzullin, Cecilie J. Sandberg, Matthew Spreadbury, Birthe Mikkelsen Saberniak, Zanina Grieg, Erlend Skaga, Iver A. Langmoen, Einar O. Vik-Mo
Publikováno v:
Translational Oncology, Vol 12, Iss 1, Pp 122-133 (2019)
BACKGROUND: Tumor cell invasion is a hallmark of glioblastoma (GBM) and a major contributing factor for treatment failure, tumor recurrence, and the poor prognosis of GBM. Despite this, our understanding of the molecular machinery that drives invasio
Externí odkaz:
https://doaj.org/article/0af2052a07984b2e92e35d74c67676d5
Autor:
Awais A. Mughal, Lili Zhang, Artem Fayzullin, Andres Server, Yuping Li, Yingxi Wu, Rainer Glass, Torstein Meling, Iver A. Langmoen, Trygve B. Leergaard, Einar O. Vik-Mo
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 20, Iss 7, Pp 643-656 (2018)
BACKGROUND: Widespread infiltration of tumor cells into surrounding brain parenchyma is a hallmark of malignant gliomas, but little data exist on the overall invasion pattern of tumor cells throughout the brain. METHODS: We have studied the invasive
Externí odkaz:
https://doaj.org/article/e7d8f0c670ea40aa9340e000e558579b
Autor:
Einar O. Vik-Mo, Alba Corell, Asgeir Store Jakola, Kristin Sjåvik, Gregor Tomasevic, Ole Solheim, Eduardo Erasmo Mendoza Mireles, Eirik Helseth, Mina Lundborg, Anja Smits, Rickard L. Sjöberg, Jon Ramm-Pettersen, Peter Milos, Ruby Mahesparan, Tomás Gómez Vecchio, Øystein Vesterli Tveiten, Sasha Gulati, Björn Sjögren, Øyvind Salvesen, Eddie de Dios, Lars Kjelsberg Pedersen, Margret Jensdottir, Bodil Karoline Ravn Munkvold, Henrietta Nittby Redebrandt, Klas Holmgren, Jiri Bartek, Maria Zetterling
Publikováno v:
Neuro-Oncology Practice
Background Early extensive surgery is a cornerstone in treatment of diffuse low-grade gliomas (DLGGs), and an additional survival benefit has been demonstrated from early radiochemotherapy in selected “high-risk” patients. Still, there are a numb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e68871be1cd606be27390983fe875ffd
https://doi.org/10.1093/nop/npab054
https://doi.org/10.1093/nop/npab054
Autor:
Liv Cathrine Heggebø, Ida Maria Henriksen Borgen, Hillevi Rylander, Cecilie Kiserud, Tonje Haug Nordenmark, Taran Paulsen Hellebust, Morten Egeberg Evensen, Magnus Gustavsson, Christina Ramberg, Mette Sprauten, Henriette Magelssen, Hanne Blakstad, Janani Moorthy, Karin Andersson, Ingela Raunert, Thomas Henry, Cecilie Moe, Carin Granlund, Dorota Goplen, Jorunn Brekke, Tor-Christian Aase Johannessen, Tora Skeidsvoll Solheim, Kirsten Marienhagen, Øyvind Humberset, Per Bergström, Måns Agrup, Ludvig Dahl, Michael Gubanski, Helene Gojon, Carl-Johan Brahme, Isabelle Rydén, Asgeir S Jakola, Einar O Vik-Mo, Hanne C. Lie, Lars Asphaug, Maziar Hervani, Ingrid Kristensen, Corina Silvia Rueegg, Inge C Olsen, Rolf J Ledal, Eskil Degsell, Katja Werlenius, Malin Blomstrand, Petter Brandal
Publikováno v:
BMJ Open. 13:e070071
IntroductionThe use of proton therapy increases globally despite a lack of randomised controlled trials demonstrating its efficacy and safety. Proton therapy enables sparing of non-neoplastic tissue from radiation. This is principally beneficial and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb6ad25830030f8f23a285481e10dc8a
https://doi.org/10.1136/bmjopen-2022-070071
https://doi.org/10.1136/bmjopen-2022-070071